UBS Group Raises Insmed (NASDAQ:INSM) Price Target to $110.00

Insmed (NASDAQ:INSM) had its price objective upped by equities researchers at UBS Group from $105.00 to $110.00 in a report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. UBS Group’s price target suggests a potential upside of 46.88% from the stock’s previous close.

Several other equities analysts have also commented on INSM. Morgan Stanley increased their price objective on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Guggenheim reiterated a “buy” rating and set a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. HC Wainwright reiterated a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Friday, February 21st. Stifel Nicolaus reduced their price objective on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a research report on Friday, February 21st. Finally, Wells Fargo & Company increased their price objective on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $93.33.

Insmed Price Performance

Shares of NASDAQ INSM opened at $74.89 on Thursday. The firm has a market capitalization of $13.56 billion, a P/E ratio of -13.40 and a beta of 1.28. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The stock’s 50-day simple moving average is $75.66 and its two-hundred day simple moving average is $73.83. Insmed has a twelve month low of $21.92 and a twelve month high of $84.91.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The business had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. As a group, equities analysts anticipate that Insmed will post -4.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other Insmed news, CEO William Lewis sold 18,750 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total value of $1,309,500.00. Following the completion of the sale, the chief executive officer now owns 384,960 shares in the company, valued at approximately $26,885,606.40. This trade represents a 4.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $80.00, for a total value of $7,291,200.00. Following the completion of the sale, the insider now owns 97,083 shares of the company’s stock, valued at approximately $7,766,640. This trade represents a 48.42 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 550,957 shares of company stock worth $42,859,028. 4.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Jennison Associates LLC raised its position in shares of Insmed by 0.6% in the 4th quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock worth $53,424,000 after acquiring an additional 4,560 shares in the last quarter. Capital CS Group LLC bought a new position in shares of Insmed in the 4th quarter worth approximately $586,000. Orion Portfolio Solutions LLC raised its position in shares of Insmed by 48.5% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock worth $2,050,000 after acquiring an additional 9,170 shares in the last quarter. Ally Bridge Group NY LLC raised its position in shares of Insmed by 16.9% in the 3rd quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock worth $11,011,000 after acquiring an additional 21,833 shares in the last quarter. Finally, TimesSquare Capital Management LLC bought a new position in shares of Insmed in the 3rd quarter worth approximately $35,322,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.